Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: A report from the American College of Surgeons Oncology Group (ACOSOG) special populations committee

Cancer

Volumn 106, Issue 1, 2006, Pages 188-195

  Newman, Lisa A ^a,h   Lee, Cheryl T ^a   Parekh, Lina Patel ^b   Stewart, Andrew K ^b   Thomas Jr , Charles R ^c   Beltran, Robert A ^d   Lucci, Anthony ^e   Green, Bettye ^d   Ota, David ^f   Nelson, Heidi ^g  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b AMERICAN COLLEGE OF SURGEONS   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Latino Med Policy Group   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MAYO CLINIC   (United States)

^h UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Breast cancer; Colorectal cancer; Disease stage; Ethnicity; Minority; National Cancer Data Base; Nonsmall cell lung cancer; Prostate cancer

Indexed keywords

AFRICAN AMERICAN; ARTICLE; BREAST CANCER; CANCER REGISTRY; CANCER RESEARCH; CLINICAL RESEARCH; COLORECTAL CANCER; ETHNOLOGY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; LUNG NON SMALL CELL CANCER; MINORITY GROUP; PRIORITY JOURNAL; PROSTATE CANCER; UNITED STATES;

AMERICAN CANCER SOCIETY; CLINICAL TRIALS; DATABASES, FACTUAL; HUMANS; MINORITY GROUPS; NEOPLASMS; PATIENT SELECTION; UNITED STATES;

EID: 29744432215     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21592     Document Type: Article

References (31)

1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality-All COD, Public-Use With State, Total U.S. for Expanded Races/Hispanics (1990-2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004. Underlying mortality data provided by NCHS (Available at URL:www.cdc.gov/nchs). 2004.
2. U.S. Census Bureau. Current population survey, 2002 to 2004 annual social and economic supplements. Washington, DC: U.S. Census Bureau. Available at URL: http://www. census.gov [Accessed 2004].
3. Bishaw A, Iceland J. Poverty:1999. In: U.S. Census Bureau. Census 2000 Brief Series, C2KBR-19. Washington, DC: U.S. Census Bureau, 2003.
4. U.S. Census Bureau. Population by race and Hispanic or Latino origin, for all ages and for 18 years and over, for the United States: 2000. Washington, DC: U.S. Census Bureau, published online January 21, 2005. Available at URL: http:// www.census.gov
5. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78-93.
6. National Institutes of Health. Public Law 103-43, the National Institutes of Health Revitalization Act of 1993. 1993:103-143.
7. Adams-Campbell LL, Ahaghotu C, Gaskins M, et al. Enrollment of African Americans onto clinical treatment trials: study design barriers. J Clin Oncol. 2004;22:730-734.
8. HarrisInteractive. Misconceptions and lack of awareness greatly reduce recruitment for cancer clinical trials. January 22, 2001;1: Available at URL: http://www.harrisinteractive. com/news/newsletters/healthnews/ HIHealthCareNews200/ Volliss3.pdf [accessed November 2005].
9. Hussain-Gambles M, Atkin K, Leese B. Why ethnic minority groups are under-represented in clinical trials: a review of the literature. Health Soc Care Community. 2004;12:382-388.
10. Hutchins L, Unger J, Crowley J, Coltman C, Albain K. Underrepresentation of patients 65 years of age older in cancer treatment trials. N Engl J Med. 1999;341:2061-2067.
11. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291:2720-2726.
12. Newman LA, Hurd T, Leitch M, et al. A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. J Am Coll Surg. 2004;199:644-651.
13. Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002;20:2109-2117.
14. Simon MS, Du W, Flaherty L, et al. Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol. 2004;22:2046-2052.
15. Swanson GM, Bailar JC 3rd. Selection and description of cancer clinical trials participants-science or happenstance? Cancer. 2002;95:950-959.
16. Tejeda HA, Green SB, Trimble EL, et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst. 1996;88:812-816.
17. American Joint Commission on Cancer. AJCC comparison guide: cancer staging manual fifth versus sixth edition. New York: Springer Verlag, 2004.
18. Peterson ED, Lytle BL, Biswas MS, Coombs L. Willingness to participate in cardiac trials. Am J Geriatr Cardiol. 2004;13:11-15.
19. Beswick AD, Rees K, Griebsch I, et al. Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups. Health Technol Assess. 2004;8:iii-iv, ix-x, 1-152.
20. Bartlett C, Davey P, Dieppe P, Doyal L, Ebrahim S, Egger M. Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001. Heart. 2003;89:327-328.
21. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162:1682-1688.
22. Alvidrez J, Arean PA. Psychosocial treatment research with ethnic minority populations: ethical considerations in conducting clinical trials. Ethics Behav. 2002;12:103-116.
23. Miskimen T, Marin H, Escobar J. Psychopharmacological research ethics: special issues affecting US ethnic minorities. Psychopharmacology (Berl). 2003;171:98-104.
24. Miranda J, Nakamura R, Bernai G. Including ethnic minorities in mental health intervention research: a practical approach to a long-standing problem. Cult Med Psychiatry. 2003;27:467-486.
25. Gifford AL, Cunningham WE, Heslin KC, et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med. 2002;346:1373-1382.
26. Betancourt JR. Cultural competence-marginal or main-stream movement? N Engl J Med. 2004;351:953-955.
27. Chirikos TN, Ruckdeschel JC, Krischer JP. Impact of clinical trials on the cost of cancer care. Med Care. 2001;39:373-383.
28. Fireman BH, Fehrenbacher L, Gruskin EP, Ray GT. Cost of care for patients in cancer clinical trials. J Natl Cancer Inst. 2000;92:136-142.
29. Bennett CL, Stinson TJ, Vogel V, et al. Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project. J Clin Oncol. 2000;18:2805-2810.
30. Gaskin DJ, Hadley J. Population characteristics of markets of safety-net and nonsafety-net hospitals. J Urban Health. 1999;76:351-370.
31. U.S. Census Bureau. U.S. Interim projections by age, sex, race, and Hispanic origin. Washington DC: U.S. Census Bureau, published online March 18, 2004. Available at URL: http://www.census.gov/ipc/www/usinterimproj/